Jason Zemansky
Stock Analyst at B of A Securities
(4.86)
# 70
Out of 4,969 analysts
42
Total ratings
76.67%
Success rate
40.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jason Zemansky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HOWL Werewolf Therapeutics | Maintains: Buy | $9 → $8 | $1.34 | +497.01% | 5 | Aug 25, 2025 | |
| RCKT Rocket Pharmaceuticals | Upgrades: Buy | $4 → $10 | $3.21 | +212.01% | 2 | Aug 20, 2025 | |
| INSM Insmed | Maintains: Buy | $94 → $109 | $142.00 | -23.24% | 10 | Jun 11, 2025 | |
| KROS Keros Therapeutics | Downgrades: Neutral | $32 → $18 | $15.45 | +16.50% | 2 | Jun 10, 2025 | |
| CYTK Cytokinetics | Maintains: Neutral | $62 → $54 | $49.34 | +9.44% | 4 | Apr 15, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $29 → $31 | $19.91 | +55.70% | 4 | Apr 1, 2025 | |
| RCUS Arcus Biosciences | Maintains: Neutral | $22 → $17 | $11.49 | +47.95% | 5 | Feb 19, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $36 → $29 | $8.05 | +260.25% | 2 | Nov 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $31 | $15.90 | +94.97% | 3 | Aug 15, 2024 | |
| ESPR Esperion Therapeutics | Downgrades: Underperform | $2.9 → $2.5 | $2.45 | +2.25% | 5 | Jun 20, 2024 |
Werewolf Therapeutics
Aug 25, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $1.34
Upside: +497.01%
Rocket Pharmaceuticals
Aug 20, 2025
Upgrades: Buy
Price Target: $4 → $10
Current: $3.21
Upside: +212.01%
Insmed
Jun 11, 2025
Maintains: Buy
Price Target: $94 → $109
Current: $142.00
Upside: -23.24%
Keros Therapeutics
Jun 10, 2025
Downgrades: Neutral
Price Target: $32 → $18
Current: $15.45
Upside: +16.50%
Cytokinetics
Apr 15, 2025
Maintains: Neutral
Price Target: $62 → $54
Current: $49.34
Upside: +9.44%
Travere Therapeutics
Apr 1, 2025
Maintains: Buy
Price Target: $29 → $31
Current: $19.91
Upside: +55.70%
Arcus Biosciences
Feb 19, 2025
Maintains: Neutral
Price Target: $22 → $17
Current: $11.49
Upside: +47.95%
Kura Oncology
Nov 22, 2024
Maintains: Buy
Price Target: $36 → $29
Current: $8.05
Upside: +260.25%
Syndax Pharmaceuticals
Aug 15, 2024
Maintains: Buy
Price Target: $30 → $31
Current: $15.90
Upside: +94.97%
Esperion Therapeutics
Jun 20, 2024
Downgrades: Underperform
Price Target: $2.9 → $2.5
Current: $2.45
Upside: +2.25%